Study identifier:D9603R00021
ClinicalTrials.gov identifier:NCT06575517
EudraCT identifier:N/A
CTIS identifier:N/A
A multifaceted intervention to improve bleeding management among patients using oral anticoagulants (IMPACT-BLEEDING): a cluster-randomized trial
Bleeding
Phase 4
No
-
All
168
Observational
18 Years - 100 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2025 by AstraZeneca
AstraZeneca
-
Prospective, cluster randomized trial including expected 168 patients with chronic use of oral anticoagulation (OAC) suffering major bleeding. Randomization will be performed stratified by geographic region (Southern/Southeastern Brazil versus other Brazilian regions).
The Group 1 in this trial will consist of a multifaceted bundle of instructions to sites about optimal management of bleeding, including transfusion thresholds and when indicated; laboratory assessment of coagulation when indicated; reversal agents when indicated, and tailored approach to restarting of oral anticoagulation and dosing adjustments among patients after bleeding episode. This bundle will be based on a society guideline on bleeding management from the American College of Cardiology. The Group 2 will be randomized to the standard of care. Standard of care will be left to the discretion of the sites (clusters) participating in the study. All sites, including those from the control group, will be encouraged to follow local policies of blood product utilization and bleeding management.
No locations available
Arms | Assigned Interventions |
---|---|
Group 1 The Group 1 in this trial will consist of a multifaceted bundle of instructions to sites about optimal management of bleeding. | - |
Group 2 The Group 2 will be randomized to the standard of care. Standard of care will be left to the discretion of the sites (clusters) participating in the study. | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.